He is a walking Rolodex of some of the nation’s most high-powered business leaders. And he’s the reason many startups feel they’ve gotten a leg up in an otherwise crushing entrepreneurial race.
Chinese investors are pumping money into US drug startups as Beijing seeks to become a global leader in new medicines, adding to a flood of cash flowing to groundbreaking health firms.
More than a dozen biotech companies or researchers from the Maryland biotech cluster, which some have also dubbed ‘Vaccine Alley’, were among the most recognized finalists at this year’s Vaccine Industry Excellence (ViE) Awards in Washington, DC at the World Vaccine Conference. In fact, 15 out of the 54 finalists, or 27%. were from right here in Maryland. This year’s conference was held in Washington, DC so could this have been a case of home court advantage? Probably not. More than likely it’s because this region holds 20% of the top influencers worldwide in vaccine development.
We hear a lot these days about the so-called “rise of the rest”—the ascent of second-tier American cities such as Pittsburgh, St. Louis, Detroit, and Nashville as challengers to the established tech capitals of the Bay Area, New York, Boston, and Seattle. But the reality is that the rise of the rest is happening mainly in cities outside of the United States.
On Tuesday, April 3, 2018 TEDCO Incubation Challenge finalist FounderTrac had their first Demo Day at Host Sponsor Loews Annapolis Hotel. After a 12 week, rigorous program 10 FounderTrac finalists pitched to a standing room only atrium of over 200 attendees. Over 50 angel investors and venture capitalists were in attendance creating an energy at the event that truly represents the essence of entrepreneurship. Tami Howie, CEO of the Maryland Technology Council says, “We had a huge number of high quality investors attend our showcase to see the amazing growth of our companies over the last 12 weeks of our FounderTrac program.”
Venture capital funds based in China poured US$1.4 billion into private US biotechnology firms in the three months ending March 31, accounting for about 40 per cent of the US$3.7 billion that the companies raised in the period overall, according to data provider PitchBook.
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a proud member of Manufacturing USA® is pleased to welcome Genentech, Celgene, Merck, MilliporeSigma and EMD Serono (the U.S. businesses of Merck KGaA, Darmstadt, Germany), among others, to its growing membership base.
The first quarter of 2018 saw a decline in investments, given that global deal activity decreased by 4 percent. Despite the fewer deals, global investment reached $46.5 billion, invested across 2,884 deals. The data was revealed as part of a larger report titled Money Tree, put together by CB Insights and PricewaterhouseCoopers, with focus on the latest trends in venture capital funding globally.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|